Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma

This trial tests a genetically engineered immune cell therapy (NK cells from cord blood) for people with multiple myeloma that has come back or stopped responding to many previous treatments. These NK cells are designed to find and kill myeloma cells that carry a protein called NY-ESO-1. **You may be eligible if...** - You have multiple myeloma with NY-ESO-1 protein detected on your cancer cells - You carry the HLA-A*02:01 genetic tissue type - Your cancer has relapsed or stopped responding to 4 or more prior treatments, including a proteasome inhibitor, an IMiD, an anti-CD38 antibody, and a BCMA-targeted therapy - You have measurable disease **You may NOT be eligible if...** - Your myeloma cells do not express NY-ESO-1 - You do not have the HLA-A*02:01 tissue type - You have had fewer than 4 prior lines of therapy - You have a solitary plasmacytoma rather than multiple myeloma Talk to your doctor to see if this trial is right for you.